Article
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Cancer science - 1 Jan 2017
Taniguchi Hirokazu, Takeuchi Shinji, Fukuda Koji, Nakagawa Takayuki, Arai Sachiko, Nanjo Shigeki, Yamada Tadaaki, Yamaguchi Hiroyuki, Mukae Hiroshi, Yano Seiji
Abstract excerpt
Crizotinib, a first-generation anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor, is known to be effective against echinoderm microtubule-associated protein-like 4 (EML4)-ALK-positive non-small cell lung cancers. Nonetheless, the tumors subsequently become resistant to crizotinib and recur in almost every case. The mechanism of the acquired resistance needs to be deciphered. In this study, we established...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.